VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Stock Comparison

ChemoMetec A/S vs Novo Nordisk A/S

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

ChemoMetec A/S

CHEMM · Nasdaq Copenhagen A/S

Market cap (USD)
Gross margin (TTM)
Operating margin (TTM)
Net margin (TTM)
SectorHealthcare
Industry
CountryDK
Data as of2026-04-24
Moat score
67/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into ChemoMetec A/S's moat claims, evidence, and risks.

View CHEMM analysis

Novo Nordisk A/S

NOVOB · Nasdaq Copenhagen

Market cap (USD)$169.9B
Gross margin (TTM)81%
Operating margin (TTM)41.3%
Net margin (TTM)33.1%
SectorHealthcare
IndustryBiotechnology
CountryDK
Data as of2025-12-28
Moat score
85/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Novo Nordisk A/S's moat claims, evidence, and risks.

View NOVOB analysis

Comparison highlights

  • Moat score gap: Novo Nordisk A/S leads (85 / 100 vs 67 / 100 for ChemoMetec A/S).
  • Segment focus: ChemoMetec A/S has 2 segments (94.8% in Life science research, cell and gene therapy, and bioprocessing); Novo Nordisk A/S has 3 segments (71.1% in Diabetes care).
  • Moat breadth: ChemoMetec A/S has 4 moat types across 2 domains; Novo Nordisk A/S has 5 across 3.

Primary market context

ChemoMetec A/S

Life science research, cell and gene therapy, and bioprocessing

Market

Global cell counting and analysis instruments for LCB workflows

Geography

Global, skewed to USA/Canada and Europe

Customer

Pharmaceutical, biotech, cell and gene therapy, bioprocessing, and research labs

Role

OEM instrument, consumables, software, and service provider

Revenue share

94.8%

Novo Nordisk A/S

Diabetes care

Market

Diabetes pharmaceuticals (GLP-1 for type 2 diabetes, insulin, and related therapies)

Geography

Global

Customer

Payers/providers and patients (via wholesalers/pharmacies/hospitals)

Role

Originator pharma (R&D, regulatory, manufacturing, commercialization)

Revenue share

71.1%

Side-by-side metrics

ChemoMetec A/S
Novo Nordisk A/S
Ticker / Exchange
CHEMM - Nasdaq Copenhagen A/S
NOVOB - Nasdaq Copenhagen
Market cap (USD)
n/a
$169.9B
Gross margin (TTM)
n/a
81%
Operating margin (TTM)
n/a
41.3%
Net margin (TTM)
n/a
33.1%
Sector
Healthcare
Healthcare
Industry
n/a
Biotechnology
HQ country
DK
DK
Primary segment
Life science research, cell and gene therapy, and bioprocessing
Diabetes care
Market structure
Oligopoly
Oligopoly
Market share
15%-25% (estimated)
33.7% (reported)
HHI estimate
n/a
n/a
Pricing power
Moderate
Moderate
Moat score
67 / 100
85 / 100
Moat domains
Demand, Network
Legal, Supply, Demand
Last update
2026-04-24
2025-12-28

Moat coverage

Shared moat types

Brand Trust

ChemoMetec A/S strengths

Installed Base ConsumablesDesign In QualificationInteroperability Hub

Novo Nordisk A/S strengths

IP Choke PointRegulated Standards PipeCapacity MoatLearning Curve Yield

Segment mix

ChemoMetec A/S segments

Full profile >

Life science research, cell and gene therapy, and bioprocessing

Oligopoly

94.8%

Production control and quality control of animal semen, beer and milk

Quasi-Monopoly

5.2%

Novo Nordisk A/S segments

Full profile >

Diabetes care

Oligopoly

71.1%

Obesity care

Duopoly

22.4%

Rare disease

Oligopoly

6.4%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.